Preclinical
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
Enzyvant Sciences, one of Vivek Ramaswamy’s numerous ‘Vant’ companies, filed a rolling submission of a Biologics License Application (BLA) for RVT-802 with the U.S. Food and Drug Administration for the treatment of DiGeorge Anomaly (cDGA), an immunodeficiency disease that impacts infants.
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
After waiting with bated breath, Johnson & Johnson Innovation finally opened its New York City JLABS facility with 26 resident companies, including the four winners of the JLABS @ NYC QuickFire Challenge.
Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.
San Diego-based Bloom Science launched to develop epilepsy treatments based on a new class of neuroprotective drugs. The company, whose research was published in the journal Cell today, focuses on gut bacteria involved in the anti-seizure effects of the ketogenic diet.
EIP Pharma, based in Cambridge, Massachusetts, closed on a $20.5 million Series B financing. The round was led by Access Industries.
Medigene and bluebird bio announced they are expanding a strategic research and development collaboration inked in September 2016.
Alnylam Pharmceuticals reported preclinical results that supports advancement of its RNA interference (RNAi) therapeutics for central nervous system disorders into the clinic.
PRESS RELEASES